Better Buy: Alnylam Pharmaceuticals vs. Ionis Pharmaceuticals

Better Buy: Alnylam Pharmaceuticals vs. Ionis Pharmaceuticals


Treating diseases that have a genetic component by altering the expression of the responsible genes is a promising new field of medicine, but it has been much less straightforward than biopharmaceutical companies had expected. Two contenders in this area, Alnylam Pharmaceuticals In 2016, these two stocks have taken paths as varied as their approaches to drug development, and the past few months have been a wild ride.



from Biotech News